Contribution of PET/MRI in Locally Advanced Cervical Cancer (ATICC) - Trial NCT06083103
Access comprehensive clinical trial information for NCT06083103 through Pure Global AI's free database. This phase not specified trial is sponsored by Institut de cancérologie Strasbourg Europe and is currently Not yet recruiting. The study focuses on Cervical Cancer. Target enrollment is 50 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Institut de cancérologie Strasbourg Europe
Timeline & Enrollment
N/A
Oct 02, 2023
Dec 31, 2025
Primary Outcome
Compare performances of PET/MRI and PET/CT in the detection of lumbar aortic lymph node metastases in cervical cancer patients with tumors graded IB2 to IVA stage
Summary
[18 F]fluorodeoxyglucose (18F-FDG) positron emission tomography-magnetic resonance imaging
 (PET/MRI) is a new hybrid imaging tool that has recently arrived in oncology, and is
 particularly promising. Its usefulness seems obvious in certain tumor types, but its place in
 the staging of cervical cancers has never been explored in a prospective trial to our
 knowledge.
 
 Previously, a comparative retrospective study from 2009 found a better sensitivity of PET
 fused to diagnostic MRI images compared to PET/CT (positron emission tomography/computed
 tomography) in the detection of metastatic lymph nodes (54 and 44% respectively). It was an a
 posteriori fusion of images, from images acquired by PET-CT.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06083103
Non-Device Trial